Merck's Biosims Business: What's For Sale And Who Will Buy It?

Merck KGaA is getting out of biosimilars – a unit that CEO Stefan Oschmann called the company's now redundant back up plan – to instead focus on its growing oncology pipeline, which includes recently acquired pipeline candidates from Vertex Pharma.

For Sale sign
Merck puts biosimilar unit portfolio up for sale • Source: Shutterstock

Merck KGaA is in "advanced discussions" to divest its biosimilars business unit – which includes a copycat version of AbbVie Inc.'s best-selling immunology drug Humira (adalimumab) – as part of an ongoing restructuring process, the company announced during its March 9 annual results presentation. The divesture of this unit would also cut down on R&D costs to the company, which said it spent around €130m on biosimilars in 2016; mostly on R&D, as well as on manufacturing work and preparation for commercialization.

At present, Merck has no revenue streams from its biosimilar drugs but its biosimilar adalimumab product, MSB11022, is in Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.